Image source: Adobe Stock/Svitlana
Neoadjuvant chemotherapy (NACT) is increasingly used in breast cancer. The best proof of NACT efficacy is pathological complete response (pCR), i.e. the absence of invasive tumour on post-NACT on surgical histopathology. "While it is known that physical exercise can help patients to better tolerate often harsh cancer treatments, it is an emerging area of research to understand if and how exercise exerts anti-tumour effects and improves oncological outcomes", says Jana de Boniface, principal investigator of the trial and associate professor in the Breast Surgery Group, Department of Molecular Medicine and Surgery.
The Neo-ACT trial opened for recruitment in September 2022, and it is estimated that inclusion may be completed in December 2025. A trial protocol has been published in the journal PLOS One.
Source: Karolinska Institutet